Stryker CEO Kevin Lobo said the company had a “very active deal pipeline” on an earnings call in July. The focus was on smaller acquisitions and fast-growing assets, Lobo said. The Nico buyout is the latest in a series of deals that fit Lobo’s description. Stryker agreed to buy Artelon for its soft tissue repair technology in June and inked deals to acquire patient monitoring firm Care.ai and back pain player Vertos Medical in August.

The Nico acquisition gives Stryker control of the Brainpath and Myriad products used in the treatment of intracerebral hemorrhages. A clinical trial that tested the devices in the minimally invasive removal of clots suggested the approach achieves better outcomes than the standard of care.